Mrinali Shetty
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mrinali Shetty has a total of 114 co-authors. Here are the top co-authors by number of shared publications:
- Andrew J. Einstein
Division of Cardiology, Department of Medicine, and Department of Radiology, Columbia University Irving Medical Center and New York-Presbyterian Hospital (A.J.E.).
5 shared publications - Yosef A. Cohen
Seymour, Paul and Gloria Milstein Division of Cardiology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center and NewYork-Presbyterian Hospital, New York; Department of Epidemiology, Mailman School of Public Health, Columbia University Irving Medical Center, New York; Department of Pediatrics, Montefiore Medical Center, Bronx
4 shared publications - Kevin J. O'GOrman
Department of Medicine, Uniformed Services University F. Edward Hébert School of Medicine, Bethesda, MD, United States; Seymour, Paul and Gloria Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center and New York-Presbyterian Hospital, New York, NY, United States
2 shared publications - Michelle Castillo
Seymour, Paul and Gloria Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center and NewYork-Presbyterian Hospital, New York, NY, United States
2 shared publications - Nishant R. Shah
Division of Cardiology, Department of Medicine, Brown University Alpert Medical School, Providence, RI, USA
2 shared publications - Adam Bernheim
From the Department of Radiology, Children’s National Hospital, Washington, DC (D.B.); Department of Radiology and Imaging Sciences (E.A.B.) and Department of Medicine, Division of Pulmonary and Critical Care Medicine (S.V.), Emory University, Atlanta, Ga; Department of Radiology, Massachusetts General Hospital, Boston, Mass (A.S., J.B.A., B.P.L.); and Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, NY (A.B., M.C.).
1 shared publication
Latest Publications
- 30 June 2026
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 62, 102797
Normal Values for 13N-Ammonia PET-derived Metrics in Heart Transplant Patients
- 30 June 2026
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 62, 102797
Normal Values for 13N-Ammonia PET-derived Metrics in Heart Transplant Patients
- 1 April 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 18 (4) , e017567
Temporal Trends in Noninvasive and Invasive Cardiac Testing From 2010 to 2022 in the US Medicare Population
BACKGROUND: Cardiac diagnostic testing continues to evolve, and controversies remain regarding the optimal utilization of different procedures. We sought to evaluate changes in long-term utilization trends for a wide range of cardiac diagnostic tests in the context of advancing technologies and updated guidelines. METHODS: Annual cardiac testing volumes from 2010 to 2022 in the Medicare Part B population were compared across tests and by provider specialty and analyzed using Joinpoint regression. RESULTS: The most-utilized test in the Medicare population remained transthoracic echocardiography, accounting for 61.5% of cardiac testing use in 2011 and 67.7% in 2022, followed by single-photon emission computed tomography (CT) myocardial perfusion imaging, which decreased from 20.8% to 12.9%. Single-photon emission CT myocardial perfusion imaging use decreased relative to positron emission tomography myocardial perfusion imaging (ratio of 39:1 in 2011 to 7:1 in 2022), stress cardiac magnetic resonance (1179:1 in 2011, 268:1 in 2022), and coronary CT angiography (61:1 in 2011, 10:1 in 2022). Decreased use was also observed for exercise treadmill testing (2.3% to 1.7%), stress echocardiography (3.6% to 2.6%), multigated acquisition (0.4% to 0.1%), and invasive coronary angiography (8.0% to 7.0%). The use of fractional flow reserve by CT per 100 000 Medicare enrollees increased by >16-fold from 2018 (the first year covered) to 2022, and cardiac amyloidosis pyrophosphate scintigraphy studies increased 4-fold from 2011 to 2022 (0.17% to 0.68%). Positron emission tomography myocardial perfusion imaging volumes have surpassed exercise treadmill test volumes and, assuming the current rate of change continues, are projected to surpass stress echocardiography volumes in 2024. Coronary CT angiography is projected to overtake exercise treadmill testing in 2024 and stress echocardiography in 2025. CONCLUSIONS: Between 2010 and 2022, cardiac diagnostic testing in the US Medicare population shifted from invasive angiography and traditional stress testing toward an increase in cardiac CT, cardiac magnetic resonance, and positron emission tomography. Pyrophosphate scintigraphy studies also increased, as did fractional flow reserve by CT since its introduction. Changes in preferred diagnostic modalities suggest a need to reevaluate current recommendations for training in cardiovascular medicine.
- 1 April 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 18 (4) , e017567
Temporal Trends in Noninvasive and Invasive Cardiac Testing From 2010 to 2022 in the US Medicare Population
BACKGROUND: Cardiac diagnostic testing continues to evolve, and controversies remain regarding the optimal utilization of different procedures. We sought to evaluate changes in long-term utilization trends for a wide range of cardiac diagnostic tests in the context of advancing technologies and updated guidelines. METHODS: Annual cardiac testing volumes from 2010 to 2022 in the Medicare Part B population were compared across tests and by provider specialty and analyzed using Joinpoint regression. RESULTS: The most-utilized test in the Medicare population remained transthoracic echocardiography, accounting for 61.5% of cardiac testing use in 2011 and 67.7% in 2022, followed by single-photon emission computed tomography (CT) myocardial perfusion imaging, which decreased from 20.8% to 12.9%. Single-photon emission CT myocardial perfusion imaging use decreased relative to positron emission tomography myocardial perfusion imaging (ratio of 39:1 in 2011 to 7:1 in 2022), stress cardiac magnetic resonance (1179:1 in 2011, 268:1 in 2022), and coronary CT angiography (61:1 in 2011, 10:1 in 2022). Decreased use was also observed for exercise treadmill testing (2.3% to 1.7%), stress echocardiography (3.6% to 2.6%), multigated acquisition (0.4% to 0.1%), and invasive coronary angiography (8.0% to 7.0%). The use of fractional flow reserve by CT per 100 000 Medicare enrollees increased by >16-fold from 2018 (the first year covered) to 2022, and cardiac amyloidosis pyrophosphate scintigraphy studies increased 4-fold from 2011 to 2022 (0.17% to 0.68%). Positron emission tomography myocardial perfusion imaging volumes have surpassed exercise treadmill test volumes and, assuming the current rate of change continues, are projected to surpass stress echocardiography volumes in 2024. Coronary CT angiography is projected to overtake exercise treadmill testing in 2024 and stress echocardiography in 2025. CONCLUSIONS: Between 2010 and 2022, cardiac diagnostic testing in the US Medicare population shifted from invasive angiography and traditional stress testing toward an increase in cardiac CT, cardiac magnetic resonance, and positron emission tomography. Pyrophosphate scintigraphy studies also increased, as did fractional flow reserve by CT since its introduction. Changes in preferred diagnostic modalities suggest a need to reevaluate current recommendations for training in cardiovascular medicine.
- Open Access
- 27 November 2024
- Published by Elsevier in JACC: Advances
- Vol. 3 (11) , 101362
Tobacco Use, Electronic Nicotine Delivery Systems, and Vulnerable Populations
- 27 November 2024
- Published by Elsevier in JACC: Advances
- Vol. 3 (11) , 101362
Open AccessTobacco Use, Electronic Nicotine Delivery Systems, and Vulnerable Populations
- 1 October 2023
- Published by Radiological Society of North America (RSNA) in Radiology: Cardiothoracic Imaging
- Vol. 5 (5) , e220288
Cardiovascular Testing in the United States during the COVID-19 Pandemic: Volume Recovery and Worldwide Comparison
To characterize the recovery of diagnostic cardiovascular procedure volumes in U.S. and non-U.S. facilities in the year following the initial COVID-19 outbreak. The International Atomic Energy Agency (IAEA) coordinated a worldwide study called the IAEA Noninvasive Cardiology Protocols Study of COVID-19 2 (INCAPS COVID 2), collecting data from 669 facilities in 107 countries, including 93 facilities in 34 U.S. states, to determine the impact of the pandemic on diagnostic cardiovascular procedure volumes. Participants reported volumes for each diagnostic imaging modality used at their facility for March 2019 (baseline), April 2020, and April 2021. This secondary analysis of INCAPS COVID 2 evaluated differences in changes in procedure volume between U.S. and non-U.S. facilities and among U.S. regions. Factors associated with return to prepandemic volumes in the United States were also analyzed in a multivariable regression analysis. Reduction in procedure volumes in April 2020 compared with baseline was similar for U.S. and non-U.S. facilities (−66% vs −71%, P = .27). U.S. facilities reported greater return to baseline in April 2021 than did all non-U.S. facilities (4% vs −6%, P = .008), but there was no evidence of a difference when comparing U.S. facilities with non-U.S. high-income country (NUHIC) facilities (4% vs 0%, P = .18). U.S. regional differences in return to baseline were observed between the Midwest (11%), Northeast (9%), South (1%), and West (−7%, P = .03), but no studied factors were significant predictors of 2021 change from prepandemic baseline. The reductions in cardiac testing during the early pandemic have recovered within a year to prepandemic baselines in the United States and NUHICs, while procedure volumes remain depressed in lower-income countries. Keywords: SPECT, Cardiac, Epidemiology, Angiography, CT Angiography, CT, Echocardiography, SPECT/CT, MR Imaging, Radionuclide Studies, COVID-19, Cardiovascular Imaging, Diagnostic Cardiovascular Procedure, Cardiovascular Disease, Cardiac Testing Supplemental material is available for this article. © RSNA, 2023
- 1 October 2023
- Published by Radiological Society of North America (RSNA) in Radiology: Cardiothoracic Imaging
- Vol. 5 (5) , e220288
Cardiovascular Testing in the United States during the COVID-19 Pandemic: Volume Recovery and Worldwide Comparison
To characterize the recovery of diagnostic cardiovascular procedure volumes in U.S. and non-U.S. facilities in the year following the initial COVID-19 outbreak. The International Atomic Energy Agency (IAEA) coordinated a worldwide study called the IAEA Noninvasive Cardiology Protocols Study of COVID-19 2 (INCAPS COVID 2), collecting data from 669 facilities in 107 countries, including 93 facilities in 34 U.S. states, to determine the impact of the pandemic on diagnostic cardiovascular procedure volumes. Participants reported volumes for each diagnostic imaging modality used at their facility for March 2019 (baseline), April 2020, and April 2021. This secondary analysis of INCAPS COVID 2 evaluated differences in changes in procedure volume between U.S. and non-U.S. facilities and among U.S. regions. Factors associated with return to prepandemic volumes in the United States were also analyzed in a multivariable regression analysis. Reduction in procedure volumes in April 2020 compared with baseline was similar for U.S. and non-U.S. facilities (−66% vs −71%, P = .27). U.S. facilities reported greater return to baseline in April 2021 than did all non-U.S. facilities (4% vs −6%, P = .008), but there was no evidence of a difference when comparing U.S. facilities with non-U.S. high-income country (NUHIC) facilities (4% vs 0%, P = .18). U.S. regional differences in return to baseline were observed between the Midwest (11%), Northeast (9%), South (1%), and West (−7%, P = .03), but no studied factors were significant predictors of 2021 change from prepandemic baseline. The reductions in cardiac testing during the early pandemic have recovered within a year to prepandemic baselines in the United States and NUHICs, while procedure volumes remain depressed in lower-income countries. Keywords: SPECT, Cardiac, Epidemiology, Angiography, CT Angiography, CT, Echocardiography, SPECT/CT, MR Imaging, Radionuclide Studies, COVID-19, Cardiovascular Imaging, Diagnostic Cardiovascular Procedure, Cardiovascular Disease, Cardiac Testing Supplemental material is available for this article. © RSNA, 2023
- Open Access
- 3 August 2023
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 10, 1103941
Chemotherapy induced right ventricular cardiomyopathy; a systematic review and meta-analysis
Background: Left ventricular dysfunction and cardiomyopathy are well documented adverse effects associated with chemotherapy agents. Limited information exists regarding the impact of chemotherapeutic agents on the integrity and function of the right ventricle (RV).Objectives: The current metanalysis compared pre- chemotherapy versus post- chemotherapy RV parameters measured on 2D echocardiography in patients receiving anthracycline and/or trastuzumab across all breast cancer patients.Methods: A systematic search across PubMed, EMBASE and Cochrane databases were performed from inception of the databases until November 2021 for relevant studies. We used the inverse variance method with a random effect model and DerSimonian and Laird method of Tau2 generation to calculate mean difference [MD] with 95% confidence interval [CI]. The analysis was carried out using RevMan Version 5.3 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014).Results: Fifteen studies, constituting total of 644 patients, met the inclusion criteria, with most studies having a follow up period of less than 12 months from initiation of chemotherapy. Anthracycline and/or Trastuzumab chemotherapy resulted in a statistically significant reduction in right ventricular ejection fraction (RVEF) at follow-up [MD: 2.70, 95% CI: 0.27 to 5.13, P-value- 0.03, I2- 71%, χ2P-value < 0.05]. Treatment with Anthracycline and/or Trastuzumab chemotherapy resulted in a significant reduction in RV fractional area change (RVFAC) at follow-up [MD: 3.74, 95% CI: 1.33 to 6.15, P-value < 0.01, I2- 68%, χ2P-value < 0.05]. RV free wall longitudinal strain (RVFWLS) was lower at baseline, while LVEF was significantly reduced at follow-up [MD: -1.00, 95% CI: -1.86 to -0.15, P-value < 0.05, I2- 0%, χ2P-value-0.40], [MD: 4.04, 95% CI: 2.08 to 6.01, P-value < 0.01, I2- 91%, χ2P-value < 0.05], respectively. However, treatment with Anthracycline and/or Trastuzumab chemotherapy had no statistically significant effect on Tricuspid annular plane systolic excursion (TAPSE) at follow-up [MD: 0.53, 95% CI: -0.11 to 1.17, P-value-0.11, I2- 98%, χ2P-value < 0.05].Conclusions: Chemotherapy with anthracyclines and trastuzumab negatively affects right ventricular function leading to decline in RVEF, RVFAC, RVFWLS and LVEF.
- 3 August 2023
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 10, 1103941
Open AccessChemotherapy induced right ventricular cardiomyopathy; a systematic review and meta-analysis
Background: Left ventricular dysfunction and cardiomyopathy are well documented adverse effects associated with chemotherapy agents. Limited information exists regarding the impact of chemotherapeutic agents on the integrity and function of the right ventricle (RV).Objectives: The current metanalysis compared pre- chemotherapy versus post- chemotherapy RV parameters measured on 2D echocardiography in patients receiving anthracycline and/or trastuzumab across all breast cancer patients.Methods: A systematic search across PubMed, EMBASE and Cochrane databases were performed from inception of the databases until November 2021 for relevant studies. We used the inverse variance method with a random effect model and DerSimonian and Laird method of Tau2 generation to calculate mean difference [MD] with 95% confidence interval [CI]. The analysis was carried out using RevMan Version 5.3 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014).Results: Fifteen studies, constituting total of 644 patients, met the inclusion criteria, with most studies having a follow up period of less than 12 months from initiation of chemotherapy. Anthracycline and/or Trastuzumab chemotherapy resulted in a statistically significant reduction in right ventricular ejection fraction (RVEF) at follow-up [MD: 2.70, 95% CI: 0.27 to 5.13, P-value- 0.03, I2- 71%, χ2P-value < 0.05]. Treatment with Anthracycline and/or Trastuzumab chemotherapy resulted in a significant reduction in RV fractional area change (RVFAC) at follow-up [MD: 3.74, 95% CI: 1.33 to 6.15, P-value < 0.01, I2- 68%, χ2P-value < 0.05]. RV free wall longitudinal strain (RVFWLS) was lower at baseline, while LVEF was significantly reduced at follow-up [MD: -1.00, 95% CI: -1.86 to -0.15, P-value < 0.05, I2- 0%, χ2P-value-0.40], [MD: 4.04, 95% CI: 2.08 to 6.01, P-value < 0.01, I2- 91%, χ2P-value < 0.05], respectively. However, treatment with Anthracycline and/or Trastuzumab chemotherapy had no statistically significant effect on Tricuspid annular plane systolic excursion (TAPSE) at follow-up [MD: 0.53, 95% CI: -0.11 to 1.17, P-value-0.11, I2- 98%, χ2P-value < 0.05].Conclusions: Chemotherapy with anthracyclines and trastuzumab negatively affects right ventricular function leading to decline in RVEF, RVFAC, RVFWLS and LVEF.
- 1 August 2023
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 16 (8) , 674-678
Gene Silencing Therapy in Hereditary (Variant) Transthyretin Cardiac Amyloidosis: A Puzzling Case of Decreasing Pyrophosphate Uptake on Scintigraphy
- 1 August 2023
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 16 (8) , 674-678
Gene Silencing Therapy in Hereditary (Variant) Transthyretin Cardiac Amyloidosis: A Puzzling Case of Decreasing Pyrophosphate Uptake on Scintigraphy
- Open Access
- 7 June 2023
- Published by Elsevier in JACC: Case Reports
- Vol. 15, 101859
Impact of Social Media and Multimedia Platforms
- 7 June 2023
- Published by Elsevier in JACC: Case Reports
- Vol. 15, 101859
Open AccessImpact of Social Media and Multimedia Platforms
- 19 April 2022
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
- Vol. 16 (4) , 355-357
Keeping up with cardiac CT: A call to action for cardiology fellowship training
- 19 April 2022
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
- Vol. 16 (4) , 355-357
Keeping up with cardiac CT: A call to action for cardiology fellowship training
- Open Access
- 1 March 2021
- Published by Elsevier in JACC: Case Reports
- Vol. 3 (3) , 357-360
Iatrogenic Atrial Septal Defect Closure Following Mitral Transcatheter Edge-to-Edge Repair
- 1 March 2021
- Published by Elsevier in JACC: Case Reports
- Vol. 3 (3) , 357-360
Open AccessIatrogenic Atrial Septal Defect Closure Following Mitral Transcatheter Edge-to-Edge Repair